Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.
AffiliationDepartment of Experimental Therapy, Netherlands Cancer Institute, Amsterdam, The Netherlands.
MetadataShow full item record
AbstractAlthough estrogen receptor-alpha (ERalpha) is a marker used to identify breast cancer patients most likely to benefit from endocrine therapy, approximately 50% of ERalpha-positive breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that phosphorylation of ERalpha at serine-118 (ERalphaS118-P) is required for tamoxifen-mediated inhibition of ERalpha-induced gene expression. We evaluated the association between recurrence-free survival after tamoxifen treatment and ERalphaS118-P expression by use of Cox proportional hazards regression. Data were from 239 premenopausal patients with breast cancer who participated in a randomized trial of 2 years of adjuvant tamoxifen treatment vs no systemic treatment. ERalphaS118-P expression was assessed by immunohistochemistry and categorized by use of the Allred score (low expression = score of 0-6; high expression = score of 7-8). All statistical tests were two-sided. Compared with systemically untreated patients, we found evidence of a benefit from adjuvant tamoxifen among patients whose tumors had high ERalphaS118-P expression (23.7 recurrences per 1000 person-years versus 72.2 recurrences per 1000 person-years, hazard ratio [HR] of recurrence = 0.36, 95% confidence interval [CI] = 0.20 to 0.65) but not among patients whose tumors had low expression (51.0 recurrences per 1000 person-years versus 57.0 recurrences per 1000 person-years, HR of recurrence = 0.87, 95% CI = 0.51 to 1.48.
CitationEstrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer. 2009, 101 (24):1725-9 J. Natl. Cancer Inst.
JournalJournal of the National Cancer Institute
- Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
- Authors: Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G
- Issue date: 2006 May 17
- Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
- Authors: Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA
- Issue date: 2011 Apr 6
- Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
- Authors: Brennan DJ, Laursen H, O'Connor DP, Borgquist S, Uhlen M, Gallagher WM, Pontén F, Millikan RC, Rydén L, Jirström K
- Issue date: 2011 Jan 31
- Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
- Authors: Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM
- Issue date: 2005 Sep 7
- Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
- Authors: International Breast Cancer Study Group., Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD
- Issue date: 2006 Mar 20